These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 31661064

  • 41. Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation.
    Obata S, Hullekes F, Riella LV, Cravedi P.
    Transplant Rev (Orlando); 2024 Jul; 38(3):100857. PubMed ID: 38749097
    [Abstract] [Full Text] [Related]

  • 42. Recurrent C3 glomerulopathy after kidney transplantation.
    Obata S, Vaz de Castro PAS, Riella LV, Cravedi P.
    Transplant Rev (Orlando); 2024 Apr; 38(2):100839. PubMed ID: 38412598
    [Abstract] [Full Text] [Related]

  • 43. Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report.
    Guzzo G, Kissling S, Pantaleo G, Pascual M, Sadallah S, Teta D.
    BMC Nephrol; 2021 Jul 06; 22(1):252. PubMed ID: 34229609
    [Abstract] [Full Text] [Related]

  • 44. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants.
    Kidney Int; 2017 Mar 06; 91(3):539-551. PubMed ID: 27989322
    [Abstract] [Full Text] [Related]

  • 45. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M, Martin Merinero H, López A, Anter J, García SP, Ataúlfo Gonzalez-Fernández F, Forés R, Lopez-Trascasa M, Villegas A, Ojeda E, Rodríguez de Córdoba S.
    Immunobiology; 2017 Feb 06; 222(2):363-371. PubMed ID: 27644115
    [Abstract] [Full Text] [Related]

  • 46. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB, Bomback AS.
    Adv Chronic Kidney Dis; 2020 Mar 06; 27(2):104-110. PubMed ID: 32553242
    [Abstract] [Full Text] [Related]

  • 47. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Mar 06; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 48. The emerging role of complement inhibitors in transplantation.
    Frémeaux-Bacchi V, Legendre CM.
    Kidney Int; 2015 Nov 06; 88(5):967-73. PubMed ID: 26376132
    [Abstract] [Full Text] [Related]

  • 49. Eculizumab in renal transplantation.
    Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, Anglicheau D.
    Transplant Rev (Orlando); 2013 Jul 06; 27(3):90-2. PubMed ID: 23747093
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Complement and kidney disease.
    Cook HT.
    Curr Opin Nephrol Hypertens; 2013 May 06; 22(3):295-301. PubMed ID: 23508058
    [Abstract] [Full Text] [Related]

  • 52. Recurrent glomerular disease after kidney transplantation.
    Blosser CD, Bloom RD.
    Curr Opin Nephrol Hypertens; 2017 Nov 06; 26(6):501-508. PubMed ID: 28832357
    [Abstract] [Full Text] [Related]

  • 53. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB.
    Clin J Am Soc Nephrol; 2012 May 06; 7(5):748-56. PubMed ID: 22403278
    [Abstract] [Full Text] [Related]

  • 54. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
.
    Riddell A, Goodship T, Bingham C.
    Clin Nephrol; 2016 Oct 06; 86(10):200-2. PubMed ID: 27616760
    [Abstract] [Full Text] [Related]

  • 55. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F, Bravo García-Morato M, Nozal P, Garrido S, Tortajada A, Rodríguez de Córdoba S, López-Trascasa M.
    Clin Exp Immunol; 2016 Apr 06; 184(1):118-25. PubMed ID: 26660535
    [Abstract] [Full Text] [Related]

  • 56. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A.
    Clin Immunol; 2017 Oct 06; 183():1-7. PubMed ID: 28647502
    [Abstract] [Full Text] [Related]

  • 57. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC.
    Kidney Int; 2017 Jun 06; 91(6):1386-1397. PubMed ID: 28139294
    [Abstract] [Full Text] [Related]

  • 58. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
    Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C.
    Front Immunol; 2019 Jun 06; 10():2166. PubMed ID: 31611870
    [Abstract] [Full Text] [Related]

  • 59. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH, Thomas AM, Bergseth G, Gustavsen A, Volokhina EB, van den Heuvel LP, Barratt-Due A, Mollnes TE.
    Mol Immunol; 2017 Sep 06; 89():111-114. PubMed ID: 28610663
    [Abstract] [Full Text] [Related]

  • 60. [Eculizumab: a shift for the treatment of glomerulonephritis with C3 deposits?].
    Esposito V.
    G Ital Nefrol; 2012 Sep 06; 29(4):377. PubMed ID: 22843144
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.